tbuckley/cabot-search huggingface dataset:
HISTORY OF RISK FACTOR CONTROL AND INCIDENT HEART FAILURE: THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY (ARIC)
Authors: Carine Hamo, Sui Zhang, Dan Wang, Roberta Florido, Justin Echouffo-Tcheugui, Roger S. Blumenthal, Laura Loehr, Kunihiro Matsushita, Vijay Nambi, Christie M. Ballantyne, Elizabeth Selvin, Aaron R. Folsom, Gerardo – Heiss, Josef Coresh, Chiadi E. Ndumele
Journal: Journal of the American College of Cardiology (2022)
Pulmonary Air Embolism in a Patient with COVID-19 with Extracorporeal Membrane Oxygenation Support.
Authors: Julia Tejero-Aranguren, Jordi Riera, María Martínez-Martínez, Eduard Argudo, Elisabet Papiol, Clara Palmada, Luis Chiscano-Camón, Abrahán Mera, Camilo Bonilla, Elisabet Gallart, Pilar Girón, Ricard Ferrer
Journal: American Journal of Respiratory and Critical Care Medicine (2022)
MULTI-MODALITY CARDIAC IMAGING OF ERDHEIM-CHESTER DISEASE
Authors: Erina Quinn, Madeline Mahowald, Patricia A. Pellikka, RONALD GO, Nandan Sadanand Anavekar, Gaurav Goyal, Nora Bennani, Mithun V. Shah, Jithma P. Abeykoon, Aldo A. Acosta-Medina, Saurabh S. Zanwar, Jason R. Young
Journal: Journal of the American College of Cardiology (2022)
SEX AND RACIAL DISPARITIES IN ARRHYTHMIA AND STROKE-RELATED HOSPITALIZATIONS AND MORTALITY IN YOUNG OBESE PATIENTS WITH OBSTRUCTIVE SLEEP APNEA: A NATIONWIDE ANALYSIS
Authors: Akhil Jain, Waleed Sultan, Nitin Ghadge, Frailyn Nunez Guzman, Crystal Moras, Rishabh Jindal, Mohammed Qaryouti, Bisharah Rizvi, Rupak Desai
Journal: Journal of the American College of Cardiology (2022)
Effect of Early Treatment with Ivermectin among Patients with Covid-19
Authors: Gilmar Reis, Eduardo A.S.M. Silva, Daniela C.M. Silva, Lehana Thabane, Aline C. Milagres, Thiago S. Ferreira, Castilho V.Q. dos Santos, Vitoria H.S. Campos, Ana M.R. Nogueira, Ana P.F.G. de Almeida, Eduardo D. Callegari, Adhemar D.F. Neto, Leonardo C.M. Savassi, Maria I.C. Simplicio, Luciene B. Ribeiro, Rosemary Oliveira, Ofir Harari, Jamie I. Forrest, Hinda Ruton, Sheila Sprague, Paula McKay, Christina M. Guo, Karen Rowland-Yeo, Gordon H. Guyatt, David R. Boulware, Craig R. Rayner, Edward J. Mills
Journal: New England Journal of Medicine (2022)

The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is unclear.We conducted a double-blind, randomized, placebo-controlled, adaptive platform trial involving symptomatic SARS-CoV-2-positive adults recruited from 12 public health clinics in Brazil. Patients who had had symptoms of Covid-19 for up to 7 days and had at least one risk factor for disease progression were randomly assigned to receive ivermectin (400 μg per kilogram of body weight) once daily for 3 days or placebo. (The trial also involved other interventions that are not reported here.) The primary composite outcome was hospitalization due to Covid-19 within 28 days after randomization or an emergency department visit due to clinical worsening of Covid-19 (defined as the participant remaining under observation for >6 hours) within 28 days after randomization.A total of 3515 patients were randomly assigned to receive ivermectin (679 patients), placebo (679), or another intervention (2157). Overall, 100 patients (14.7%) in the ivermectin group had a primary-outcome event, as compared with 111 (16.3%) in the placebo group (relative risk, 0.90; 95% Bayesian credible interval, 0.70 to 1.16). Of the 211 primary-outcome events, 171 (81.0%) were hospital admissions. Findings were similar to the primary analysis in a modified intention-to-treat analysis that included only patients who received at least one dose of ivermectin or placebo (relative risk, 0.89; 95% Bayesian credible interval, 0.69 to 1.15) and in a per-protocol analysis that included only patients who reported 100% adherence to the assigned regimen (relative risk, 0.94; 95% Bayesian credible interval, 0.67 to 1.35). There were no significant effects of ivermectin use on secondary outcomes or adverse events.Treatment with ivermectin did not result in a lower incidence of medical admission to a hospital due to progression of Covid-19 or of prolonged emergency department observation among outpatients with an early diagnosis of Covid-19. (Funded by FastGrants and the Rainwater Charitable Foundation; TOGETHER ClinicalTrials.gov number, NCT04727424.).
Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma
Authors: Weiwei Liu, Lu zheng, Rongguiyi Zhang, Ping Hou, Jiakun Wang, Linquan Wu, Jing Li
Journal: Molecular Cancer (2022)

Although the prognostic outcomes of liver cancer (LC) cases have improved with the advancement in diagnostic technology and treatment methods, the transferability and recurrence of HCC and the 5-year and 10-year survival rates of patients have remained unsatisfactory. As a result, there is a need for more accurate diagnostic indicators that can detect liver cancer early, effectively improving the prognosis of patients. Whole-genome sequencing (WGS) revealed that circ-ZEB1 and PIK3CA are highly expressed in HCC tissues, whereas miR-199a-3p is significantly downregulated in HCC. Multiple databases search and biological analysis revealed that elevated expression of circ-ZEB1 and PIK3CA was related to poor prognosis of HCC. In vitro and in vivo studies revealed that upregulated levels of PIK3CA and circ-ZEB1 were closely associated with HCC proliferation and apoptosis. Based on these results, we believe that circ-ZEB1 and PIK3CA could be used as biomarkers to diagnose and treat patients with HCC. More importantly, circ-ZEB1 can promotes the expression of PIK3CA by silencing miR-199a-3p and affecting the progression of HCC.
Error in a Figure
Journal: JAMA Network Open (2022)

Justin E. R. E. Wong Chung, MD; Rozemarie van Geet, MD; Noud van Helmond, MD, PhD; Chloé Kastoer, MD, PhD; Stefan Böhringer, MD, PhD; Wilbert B. van den Hout, PhD; Hendrik P. Verschuur, MD, PhD; Ferdinand A. W. Peek, MD; Patrick F. M. Dammeijer, MD, PhD; Gijs K. A. van Wermeskerken, MD, PhD; Peter Paul G. van Benthem, MD, PhD; Henk M. Blom, MD, PhD
IMPACT OF EVOLOCUMAB ON PERIPROCEDURAL MICROVASCULAR DAMAGE IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: THE EVOCATION TRIAL
Authors: Masaharu Ishihara, Hibi Kiyoshi, Okada Kozo, Satoru Suwa, Wataru Shimizu, Hitoshi Takano, Kenshi Fujii, Yasuo Okumura, Toshiaki Mano, Kenichi Tsujita, Masataka Igeta, Shinichiro Suna, Masanori Asakura
Journal: Journal of the American College of Cardiology (2022)
A clinician’s handbook for using ctDNA throughout the patient journey
Authors: Samantha O. Hasenleithner, Michael R. Speicher
Journal: Molecular Cancer (2022)

The promise of precision cancer medicine presently centers around the genomic sequence of a patient's tumor being translated into timely, actionable information to inform clinical care. The analysis of cell-free DNA from liquid biopsy, which contains circulating tumor DNA (ctDNA) in patients with cancer, has proven to be amenable to various settings in oncology. However, open questions surrounding the clinical validity and utility of plasma-based analyses have hindered widespread clinical adoption.Owing to the rapid evolution of the field, studies supporting the use of ctDNA as a biomarker throughout a patient's journey with cancer have accumulated in the last few years, warranting a review of the latest status for clinicians who may employ ctDNA in their precision oncology programs. In this work, we take a step back from the intricate coverage of detection approaches described extensively elsewhere and cover basic concepts around the practical implementation of next generation sequencing (NGS)-guided liquid biopsy. We compare relevant targeted and untargeted approaches to plasma DNA analysis, describe the latest evidence for clinical validity and utility, and highlight the value of genome-wide ctDNA analysis, particularly as it relates to early detection strategies and discovery applications harnessing the non-coding genome.The maturation of liquid biopsy for clinical application will require interdisciplinary efforts to address current challenges. However, patients and clinicians alike may greatly benefit in the future from its incorporation into routine oncology care.
UNDIAGNOSED STAGE 3 CHRONIC KIDNEY DISEASE IN PATIENTS WITH A HISTORY OF HEART FAILURE: A REPORT FROM REVEAL-CKD
Authors: Toshiki Moriyama, Markus Schneider, Jean Blaise J. Virgitti, Emily Peach, Salvatore Barone, Supriya Kumar, Navdeep Tangri
Journal: Journal of the American College of Cardiology (2022)
USE OF INTERNAL JUGULAR VEIN DIAMETER VARIATION AT BEDSIDE FOR ESTIMATION OF FLUID STATUS IN A PATIENT WITH LEFT VENTRICULAR ASSIST DEVICE
Authors: Nakeya Dewaswala, Huzefa Bhopalwala, Josue Villegas-Galaviz, Gaurang N. Vaidya
Journal: Journal of the American College of Cardiology (2022)
Iron deficiency linked to altered bile acid metabolism promotes Helicobacter pylori–induced inflammation–driven gastric carcinogenesis
Authors: Jennifer M. Noto, M. Blanca Piazuelo, Shailja C. Shah, Judith Romero-Gallo, Jessica L. Hart, Chao Di, James D. Carmichael, Alberto G. Delgado, Alese E. Halvorson, Robert A. Greevy, Lydia E. Wroblewski, Ayushi Sharma, Annabelle B. Newton, Margaret M. Allaman, Keith T. Wilson, M. Kay Washington, M. Wade Calcutt, Kevin L. Schey, Bethany P. Cummings, Charles R. Flynn, Joseph P. Zackular, Richard M. Peek
Journal: Journal of Clinical Investigation (2022)

Gastric carcinogenesis is mediated by complex interactions among Helicobacter pylori, host, and environmental factors. Here, we demonstrate that H. pylori augmented gastric injury in INS-GAS mice under iron-deficient conditions. Mechanistically, these phenotypes were not driven by alterations in the gastric microbiota; however, discovery-based and targeted metabolomics revealed that bile acids were significantly altered in H. pylori–infected mice with iron deficiency, with significant upregulation of deoxycholic acid (DCA), a carcinogenic bile acid. The severity of gastric injury was further augmented when H. pylori–infected mice were treated with DCA, and, in vitro, DCA increased translocation of the H. pylori oncoprotein CagA into host cells. Conversely, bile acid sequestration attenuated H. pylori–induced injury under conditions of iron deficiency. To translate these findings to human populations, we evaluated the association between bile acid sequestrant use and gastric cancer risk in a large human cohort. Among 416,885 individuals, a significant dose-dependent reduction in risk was associated with cumulative bile acid sequestrant use. Further, expression of the bile acid receptor transmembrane G protein–coupled bile acid receptor 5 (TGR5) paralleled the severity of carcinogenic lesions in humans. These data demonstrate that increased H. pylori–induced injury within the context of iron deficiency is tightly linked to altered bile acid metabolism, which may promote gastric carcinogenesis.
Clinical Utility of Precision Medicine in Early Breast Cancer: What Is the Optimal Framework to Develop Precision Medicine?
Authors: Kazuki Nozawa, Masaya Hattori, Akiyo Yoshimura, Hiroji Iwata
Journal: Journal of Clinical Oncology (2022)

In their article in the Journal of Clinical Oncology, Schneider et al 1 reported the results of the BRE12-158 trial, which confirmed that directed therapy was not superior to the treatment of physician's choice (TPC) for patients with residual triple-negative breast cancer after neoadjuvant chemotherapy.Despite the impressive results, it may have some points to consider for further discussion.
Comments on Surgeon-Patient Sex Concordance and Postoperative Outcomes
Authors: Max Jordan Nguemeni Tiako, Alexander Chaitoff, Jocelyn J. Fitzgerald
Journal: JAMA Surgery (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
ARTIFICIAL INTELLIGENCE ENABLED FULLY AUTOMATED CMR FUNCTION QUANTIFICATION FOR OPTIMIZED RISK STRATIFICATION IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Ruben Evertz, Torben Lange, Sören Jan Backhaus, Alexander Schulz, Bo Eric Beuthner, Rodi Topci, Karl Toischer, Miriam Puls, Johannes Kowallick, Gerd Hasenfuß, Andreas Schuster
Journal: Journal of the American College of Cardiology (2022)
ASSOCIATION BETWEEN 6-YEAR CHANGE IN NT-PROBNP WITH HEART FAILURE AND DEATH: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY
Authors: Xiaoming Jia, Mahmoud Al Rifai, Ron Hoogeveen, Justin E. Tcheugui, Amil M. Shah, Chiadi E. Ndumele, Salim S. Virani, Biykem Bozkurt, Elizabeth Selvin, Christie M. Ballantyne, Vijay Nambi
Journal: Journal of the American College of Cardiology (2022)
Abstract P5-07-07: Mapping clonal evolution and tumor heterogeneity by whole exome sequencing of tissue and plasma circulating tumor DNA in metastatic breast cancer
Authors: Stephanie Kavan, Torben A Kruse, Lars Andersen, Martin Larsen, Malene G Hildebrandt, Anne-Marie Bak Jylling, Marianne Ewertz, Marianne Vogsen, Mads Thomassen
Journal: Cancer Research (2022)

Abstract Tumor heterogeneity in breast cancer tumors is widely recognized but evolution of the breast cancer genome is complex and not yet understood. Characterizing the evolutionary landscape of breast tumors can provide biological understanding of tumor progression and metastasis may be important for directing effective treatments. We performed copy number profiling and mutation detection based on whole exome sequencing of primary tumors, lymph node and distant metastasis as well as on plasma circulating tumor DNA from twelve metastatic breast cancer patients. Preliminary data shows diverse patterns of tumor evolution. Although linear evolution with late dissemination of metastatic cells was common, parallel evolution with early dissemination from primary tumor to distant sites was evident in some cases. Comparing tissue biopsies with plasma samples, we could detect variants mirroring primary tumor and/or metastasis, depending on the time span between the progression steps. The genomic discordance between the different stages of tumor evolution in these patients not only emphasizes the importance of molecular profiling of metastatic tissue but also the possibilities of liquid biopsies for real-time tracking of tumor clonal evolution. Citation Format: Stephanie Kavan, Torben A Kruse, Lars Andersen, Martin Larsen, Malene G Hildebrandt, Anne-Marie Bak Jylling, Marianne Ewertz, Marianne Vogsen, Mads Thomassen. Mapping clonal evolution and tumor heterogeneity by whole exome sequencing of tissue and plasma circulating tumor DNA in metastatic breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-07-07.
Short-term exposure to ambient air pollution and individual emergency department visits for COVID-19: a case-crossover study in Canada
Authors: Eric Lavigne, Niilo Ryti, Antonio Gasparrini, Francesco Sera, Scott Weichenthal, Hong Chen, Teresa To, Greg J Evans, Liu Sun, Aman Dheri, Lionnel Lemogo, Serge Olivier Kotchi, Dave Stieb
Journal: Thorax (2022)

Ambient air pollution is thought to contribute to increased risk of COVID-19, but the evidence is controversial.To evaluate the associations between short-term variations in outdoor concentrations of ambient air pollution and COVID-19 emergency department (ED) visits.We conducted a case-crossover study of 78 255 COVID-19 ED visits in Alberta and Ontario, Canada between 1 March 2020 and 31 March 2021. Daily air pollution data (ie, fine particulate matter with diameter less than 2.5 µm (PM2.5), nitrogen dioxide (NO2) and ozone were assigned to individual case of COVID-19 in 10 km × 10 km grid resolution. Conditional logistic regression was used to estimate associations between air pollution and ED visits for COVID-19.Cumulative ambient exposure over 0-3 days to PM2.5 (OR 1.010; 95% CI 1.004 to 1.015, per 6.2 µg/m3) and NO2 (OR 1.021; 95% CI 1.015 to 1.028, per 7.7 ppb) concentrations were associated with ED visits for COVID-19. We found that the association between PM2.5 and COVID-19 ED visits was stronger among those hospitalised following an ED visit, as a measure of disease severity, (OR 1.023; 95% CI 1.015 to 1.031) compared with those not hospitalised (OR 0.992; 95% CI 0.980 to 1.004) (p value for effect modification=0.04).We found associations between short-term exposure to ambient air pollutants and COVID-19 ED visits. Exposure to air pollution may also lead to more severe COVID-19 disease.
EFFECT OF UPSTREAM DOXYCYCLINE DURING PRIMARY PERCUTANEOUS CORONARY INTERVENTION FOR ST ELEVATION MYOCARDIAL INFARCTION ON INFARCT SIZE AND LEFT VENTRICULAR REMODELLING, A RANDOMIZED CLINICAL TRIAL
Authors: Samer Noaman, Christopher Neil, Jessica O'Brien, Bing Wang, Tsin YeeTai, Michael Paul Frenneaux, James Linley Hare, Adam Gay, James Shaw, Dion Stub, Jason Bloom, Antony Walton, Stephen Duffy, Karl-Heinz Peter, Nicholas Cox, David M. Kaye, Andrew J. Taylor, William Chan
Journal: Journal of the American College of Cardiology (2022)
Author Correction: The immunoregulatory landscape of human tuberculosis granulomas
Authors: Erin F. McCaffrey, Michele Donato, Leeat Keren, Zhenghao Chen, Alea Delmastro, Megan B. Fitzpatrick, Sanjana Gupta, Noah F. Greenwald, Alex Baranski, William Graf, Rashmi Kumar, Marc Bosse, Christine Camacho Fullaway, Pratista K. Ramdial, Erna Forgó, Vladimir Jojic, David Van Valen, Smriti Mehra, Shabaana A. Khader, Sean C. Bendall, Matt van de Rijn, Daniel Kalman, Deepak Kaushal, Robert L. Hunter, Niaz Banaei, Adrie J. C. Steyn, Purvesh Khatri, Michael Angelo
Journal: Nature Immunology (2022)
NOVEL TREATMENT OF IMMUNE CHECKPOINT INHIBITOR FULMINANT MYOCARDITIS WITH RESOLUTION OF CARDIOGENIC SHOCK
Authors: Zackary Tushak, Valentina Jaramillo Restrepo, Sae Jang, Jonathan Eric Holtz, Jessica Huston, George Jabbour, Zachary Rhinehart, Joshua Eric Levenson, Mark Schmidhofer
Journal: Journal of the American College of Cardiology (2022)
Site-directed deuteration of dronedarone preserves cytochrome P4502J2 activity and mitigates its cardiac adverse effects in canine arrhythmic hearts
Authors: Aneesh V. Karkhanis, Gopalakrishnan Venkatesan, Ryuichi Kambayashi, Jacqueline Wen Hui Leow, Marcus Qingrui Han, Hiroko Izumi-Nakaseko, Ai Goto, Jeremy Kah Sheng Pang, Boon Seng Soh, Pipin Kojodjojo, Atsushi Sugiyama, Eric Chun Yong Chan
Journal: Acta Pharmaceutica Sinica B (2022)

Cytochrome P4502J2 (CYP2J2) metabolizes arachidonic acid (AA) to cardioprotective epoxyeicosatrienoic acids (EETs). Dronedarone, an antiarrhythmic drug prescribed for treatment of atrial fibrillation (AF) induces cardiac adverse effects (AEs) with poorly understood mechanisms. We previously demonstrated that dronedarone inactivates CYP2J2 potently and irreversibly, disrupts AA-EET pathway leading to cardiac mitochondrial toxicity rescuable via EET enrichment. In this study, we investigated if mitigation of CYP2J2 inhibition prevents dronedarone-induced cardiac AEs. We first synthesized a deuterated analogue of dronedarone (termed poyendarone) and demonstrated that it neither inactivates CYP2J2, disrupts AA-EETs metabolism nor causes cardiac mitochondrial toxicity in vitro. Our patch-clamp experiments demonstrated that pharmacoelectrophysiology of dronedarone is unaffected by deuteration. Next, we show that dronedarone treatment or CYP2J2 knockdown in spontaneously beating cardiomyocytes indicative of depleted CYP2J2 activity exacerbates beat-to-beat (BTB) variability reflective of proarrhythmic phenotype. In contrast, poyendarone treatment yields significantly lower BTB variability compared to dronedarone in cardiomyocytes indicative of preserved CYP2J2 activity. Importantly, poyendarone and dronedarone display similar antiarrhythmic properties in the canine model of persistent AF, while poyendarone substantially reduces beat-to-beat variability of repolarization duration suggestive of diminished proarrhythmic risk. Our findings prove that deuteration of dronedarone prevents CYP2J2 inactivation and mitigates dronedarone-induced cardiac AEs.
CHARACTERISTICS AND OUTCOMES OF ACUTE CEREBROVASCULAR EVENTS IN PATIENTS WITH CARDIOGENIC SHOCK ON TEMPORARY MECHANICAL CIRCULATORY SUPPORT
Authors: Raunak M. Nair, Bindesh Ghimire, Bahaa Abdelghaffar, Talha Saleem, Adil Vural, Hassan Mehmood Lak, Andrew Higgins, Ran Lee, Paul Cremer, Penelope Rampersad, Venu Menon
Journal: Journal of the American College of Cardiology (2022)